About
IonMed is bringing a plasma-based technology to advanced clinical stages with its BioWeld1 proprietary technology. BioWeld1 is a cold plasma device, complete with dedicated disposable tips and a biological film, that is ideally suited for wound and surgical incision closure and skin-graft fixation, with additional clinical applications in development. Once the graft is placed on the grafting site, Chitoplast strips are applied along the graft edges and adjacent tissue. Alternatively, the Chitoplast can be applied along the incision edges. Cold plasma is then applied along the Chitoplast strips, which cover the graft edges, causing hemostasis and further adherence of the Chitoplast, leading to a closer approximation of the incision or skin-graft edges. The combined actions of the plaster and plasma provide the basis for the subsequent natural healing process. IonMed's BioWeld1 is CE cleared for surgical incision closure, and the company is certified to the ISO13845 standard. The system's CE clearance for skin graft fixation application is pending.
Funding history · 2 rounds · — total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is IonMed's primary technology?
- IonMed's primary technology is BioWeld1, a cold plasma device designed for wound and surgical incision closure and skin-graft fixation.
- When was IonMed founded?
- IonMed was founded in November 2009.
- What is the operational status of IonMed?
- IonMed is currently inactive and ceased to operate in July 2019.
- Where is IonMed headquartered?
- IonMed is headquartered in Yokne'am Illit, Israel.
- Which markets did IonMed target?
- IonMed targeted geographic markets in the United States and Europe.
- What certifications does IonMed's BioWeld1 system hold?
- IonMed's BioWeld1 is CE cleared for surgical incision closure, and the company is certified to the ISO13845 standard. CE clearance for skin graft fixation is pending.
- Who were the founders of IonMed?
- The founders of IonMed were Ronen Lam and Amnon Lam.
- When did IonMed receive CE Mark Clearance for its BioWeld1 system?
- IonMed received CE Mark Clearance for its BioWeld1 Cold Plasma System in October 2014.
- When did IonMed complete its first European clinical study for surgical wound closure?
- IonMed announced the successful completion of its first European cold plasma clinical study for the closure of surgical wounds in May 2013.